AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30067323 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of botulinum toxin A
Number of subjects: 20
Study 30067323 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluation by doctor and patients
Number of subjects: 20
Study 24850111 — intervention group
Group type: EXPERIMENTAL
Intervention: IPM‐QRB criteria
Number of subjects: 4
Study 24850111 — intervention group
Group type: COMPARATOR
Intervention: Cochrane review criteria
Number of subjects: 4
Study 22901959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 184
Study 22901959 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental resection with regional lymph node dissection
Number of subjects: 184
Study 22901959 — intervention group
Group type: COMPARATOR
Intervention: Segmental resection with selected lymph node resection
Number of subjects: 184
Study 22901959 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (poor pulmonary function)
Number of subjects: 184
Study 21040375 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine (3 mg kg(‐1))
Number of subjects: 31
Study 21040375 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (1.5 mg kg(‐1))
Number of subjects: 31
Study 21040375 — intervention group
Group type: COMPARATOR
Intervention: Control group (xylazine premedication)
Number of subjects: 31
Study 21040375 — intervention group
Group type: COMPARATOR
Intervention: Control group (isoflurane maintenance)
Number of subjects: 31
Study 18657670 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 458
Study 18657670 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study 16317124 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid diet
Number of subjects: 45
Study 16317124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 45
Study 16317124 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 45
Study 11979003 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide or somatostatin
Number of subjects: 0
Study 11979003 — intervention group
Group type: COMPARATOR
Intervention: Specialist centres
Number of subjects: 0
Study 11979003 — intervention group
Group type: COMPARATOR
Intervention: Nonspecialist centres
Number of subjects: 0
Study 11979003 — intervention group
Group type: EXPERIMENTAL
Intervention: Common complications
Number of subjects: 0
Study 11979003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay
Number of subjects: 0
Study 11979003 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-operation rate
Number of subjects: 0
Study 11979003 — intervention group
Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 0
Study 9794903 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 microgram subcutaneously three times a day for 15 days
Number of subjects: 262
Study 9794903 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 262
Study 7620115 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 128
Study 7620115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 2693850 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 119
Study 2693850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine-vindesine
Number of subjects: 119
Study 323025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg physostigmine i.v.
Number of subjects: 14
Study 323025 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo i.v.
Number of subjects: 14
Study 30762190 — intervention group
Group type: EXPERIMENTAL
Intervention: myDEx intervention
Number of subjects: 180
Study 28823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental identification of normal sexualized behaviors
Number of subjects: 244
Study 28823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental identification of concerning or harmful sexualized behaviors
Number of subjects: 244
Study 28823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental intervention responses
Number of subjects: 244
Study 28823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental identification of behaviors in very young children (0-4 years)
Number of subjects: 244
Study 28823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intervention responses based on relationship to victim/perpetrator
Number of subjects: 244
Study 28823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of intervention responses when both victim and perpetrator are siblings
Number of subjects: 244
Study 24245753 — intervention group
Group type: EXPERIMENTAL
Intervention: scaling‐polishing + tooth brushing + tongue brushing
Number of subjects: 151
Study 24245753 — intervention group
Group type: COMPARATOR
Intervention: scaling‐polishing + tooth brushing
Number of subjects: 151
Study 23586374 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelium-off collagen cross-linking (CXL)
Number of subjects: 14
Study 23586374 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal microscopy
Number of subjects: 14
Study 23586374 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheimpflug imaging
Number of subjects: 14
Study 23586374 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 14
Study 23586374 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp biomicroscopy
Number of subjects: 14
Study 21281542 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored nutrition advice (Food-O-Meter)
Number of subjects: 621
Study 21281542 — intervention group
Group type: COMPARATOR
Intervention: Standardised advice (Control)
Number of subjects: 621
Study 19299903 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT with leucovorin (LV)
Number of subjects: 0
Study 19299903 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT in combination with oxaliplatin (TEGAFOX)
Number of subjects: 0
Study 19299903 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT in combination with irinotecan (TEGAFIRI)
Number of subjects: 0
Study 19299903 — intervention group
Group type: EXPERIMENTAL
Intervention: TEGAFOX and TEGAFIRI (alternating cycles)
Number of subjects: 0
Study 19299903 — intervention group
Group type: EXPERIMENTAL
Intervention: TEGAFIRI and cetuximab
Number of subjects: 0
Study 17000944 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus (DM)
Number of subjects: 97771
Study 14962401 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid preparation for the irrelevant task
Number of subjects: 0
Study 14962401 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid preparation
Number of subjects: 0
Study 11739444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 9
Study 11739444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9192957 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25-25.5 Gy over 5-7 days)
Number of subjects: 1316
Study 1532222 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 18) trained from 72 degrees to 36 degrees of lumbar flexion
Number of subjects: 58
Study 1532222 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n = 14) trained from 36 degrees to 0 degree of lumbar flexion
Number of subjects: 58
Study 1532222 — intervention group
Group type: EXPERIMENTAL
Intervention: Group AB (n = 16) trained from 72 degrees to 0 degree of lumbar flexion
Number of subjects: 58
Study 1532222 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; n = 10) that did not train
Number of subjects: 58
Study 3887870 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC (amino acid preparation)
Number of subjects: 62
Study 3887870 — intervention group
Group type: COMPARATOR
Intervention: Control (mixture of two pollen extracts)
Number of subjects: 62
Study 3887870 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC
Number of subjects: 62
Study 3887870 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 31742631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 1686
Study 31742631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 25 mg
Number of subjects: 1686
Study 31742631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study 29071969 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + nutrition consultation
Number of subjects: 71
Study 29071969 — intervention group
Group type: COMPARATOR
Intervention: Simple nutrition consultation
Number of subjects: 71
Study 25592006 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 10
Study 25592006 — intervention group
Group type: EXPERIMENTAL
Intervention: Green coffee bean extract (10 mg/kg, 5 mg/kg chlorogenic acid)
Number of subjects: 10
Study 25592006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23503735 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation therapy
Number of subjects: 50
Study 23503735 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (bronchodilators, antibiotics, oxygen, patient education)
Number of subjects: 50
Study 21472632 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week aerobic running exercise program (3 workouts per week)
Number of subjects: 16
Study 18263663 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily for 12 weeks)
Number of subjects: 746
Study 18263663 — intervention group
Group type: COMPARATOR
Intervention: Transdermal NRT (21 mg/day reducing to 7 mg/day for 10 weeks)
Number of subjects: 746
Study 18263663 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 746
Study 18263663 — intervention group
Group type: COMPARATOR
Intervention: Transdermal NRT
Number of subjects: 746
Study 16426449 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Physical Treatment (APT)
Number of subjects: 223
Study 16426449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 223
Study 16426449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (CT) of APT and CBT
Number of subjects: 223
Study 16426449 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 223
Study 12483414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor‐18 2‐fluorodeoxyglucose (FDG) imaging
Number of subjects: 15
Study 12483414 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐[(11)C‐methyl]‐L‐deuterodeprenyl (DED) imaging
Number of subjects: 15
Study 12483414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen‐15 labelled water scan
Number of subjects: 15
Study 12483414 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography and magnetic resonance imaging
Number of subjects: 15
Study 12483414 — intervention group
Group type: EXPERIMENTAL
Intervention: PET examinations
Number of subjects: 15
Study 10957749 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate consumption of red wine with evening dinner for 3 weeks
Number of subjects: 0
Study 10957749 — intervention group
Group type: COMPARATOR
Intervention: Red grape juice consumption
Number of subjects: 0
Study 8645774 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 63
Study 8645774 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 63
Study 8645774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 1468186 — intervention group
Group type: EXPERIMENTAL
Intervention: ponalrestat 600 mg/day
Number of subjects: 32
Study 1468186 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 32
Study 6731770 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedicated with TDP (trimeprazine, droperidol, physeptone, and atropine)
Number of subjects: 90
Study 6731770 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedicated with trimeprazine and atropine
Number of subjects: 90
Study 6731770 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedicated with papaveretum and hyoscine
Number of subjects: 90
Study 6731770 — intervention group
Group type: COMPARATOR
Intervention: Unpremedicated children
Number of subjects: 90
Study 3700848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 60
Study 3700848 — intervention group
Group type: COMPARATOR
Intervention: Stress inoculation training
Number of subjects: 60
Study 3700848 — intervention group
Group type: COMPARATOR
Intervention: Stress inoculation training defined as hypnosis
Number of subjects: 60
Study 29463231 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy adherence assessment
Number of subjects: 0
Study 29463231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel correlates assessment
Number of subjects: 0
Study 28606219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (mean 870 mg/d)
Number of subjects: 323
Study 26206258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with anthracyclines (epirubicin -> cyclophosphamide, methotrexate and fluorouracil (CMF))
Number of subjects: 921
Study 26206258 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without anthracyclines (CMF)
Number of subjects: 921
Study 24002795 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 10886
Study 24002795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10886
Study 21441356 — intervention group
Group type: EXPERIMENTAL
Intervention: High concurrent self-regulatory efficacy (SRE) group
Number of subjects: 49
Study 21441356 — intervention group
Group type: COMPARATOR
Intervention: Low concurrent self-regulatory efficacy (SRE) group
Number of subjects: 49
Study 17335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 13
Study 17335643 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 13
Study 17335643 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment with reduced frequency (from two sessions per day to one)
Number of subjects: 13
Study 17335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for TEM (decrease or discontinuation of antidepressant and/or rTMS treatment and/or use of anti-manic medication)
Number of subjects: 13
Study 16996855 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg candesartan cilexetil
Number of subjects: 120
Study 16996855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12790064 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative postoperative pain management techniques
Number of subjects: 0
Study 12790064 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatments for postoperative pain management
Number of subjects: 0
Study 10971422 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of ilioinguinal nerve
Number of subjects: 20
Study 10971422 — intervention group
Group type: COMPARATOR
Intervention: Division of ilioinguinal nerve
Number of subjects: 20
Study 8732473 — intervention group
Group type: COMPARATOR
Intervention: Menorest (transdermal oestradiol) at doses of 50, 75, 100 micrograms/day in study 201 and 25, 50, 75 micrograms/day in study 305, administered cyclic sequential or continuous sequential with dydrogesterone 20 mg/day during the last 14 days.
Number of subjects: 480
Study 8732473 — intervention group
Group type: COMPARATOR
Intervention: Menorest (transdermal oestradiol)
Number of subjects: 480
Study 1426355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 200 mg/d
Number of subjects: 75
Study 1426355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1000 mg/d
Number of subjects: 75
Study 1426355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 6697071 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml normal saline
Number of subjects: 0
Study 6697071 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Depomedrone in normal saline made up to 20 ml
Number of subjects: 0
Study 6697071 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.25% bupivacaine solution
Number of subjects: 0
Study 6697071 — intervention group
Group type: COMPARATOR
Intervention: Needling with a standard Touhy injection needle into the interspinous ligament (no injection)
Number of subjects: 0
Study 29294892 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to bullying and mistreatment by siblings
Number of subjects: 800
Study 29294892 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to verbal abuse and quarrel within family members
Number of subjects: 800
Study 29294892 — intervention group
Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 800
Study 29294892 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from families that always fight and parents with exposure to childhood maltreatment
Number of subjects: 800
Study 30278853 — intervention group
Group type: EXPERIMENTAL
Intervention: PS training
Number of subjects: 83
Study 30278853 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training
Number of subjects: 83
Study 30278853 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 83
Study 28166785 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial DMARD-monotherapy (sulfasalazine (SSZ) or methotrexate (MTX))
Number of subjects: 94
Study 28166785 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial MTX / prednisolone-bridging
Number of subjects: 94
Study 28166785 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination MTX/etanercept
Number of subjects: 94
Study 28166785 — intervention group
Group type: COMPARATOR
Intervention: Control group (Initial DMARD-monotherapy and Initial MTX / prednisolone-bridging)
Number of subjects: 94
Study 25476268 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders after making an appointment
Number of subjects: 1786
Study 25476268 — intervention group
Group type: COMPARATOR
Intervention: Control group received a leaflet on preparation instructions
Number of subjects: 1786
Study 25476268 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 1786
Study 23628001 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg)
Number of subjects: 0
Study 23628001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21355003 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg loading dose, 6 mg/kg every 3 weeks for 1 year) plus chemotherapy
Number of subjects: 300
Study 21355003 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab monotherapy
Number of subjects: 300
Study 21355003 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (with chemotherapy)
Number of subjects: 300
Study 19473468 — intervention group
Group type: EXPERIMENTAL
Intervention: Clitoral blood volume (CBV) measurement during erotic film clips
Number of subjects: 30
Study 19473468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal pulse amplitude (VPA) measurement during erotic film clips
Number of subjects: 30
Study 19473468 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance levels (SCL) measurement during erotic film clips
Number of subjects: 30
Study 19473468 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CBV and VPA at the end of the erotic film clip presentation
Number of subjects: 30
Study 17299516 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 115 microg/kg
Number of subjects: 16
Study 17299516 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 215 microg/kg
Number of subjects: 16
Study 17299516 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 315 microg/kg
Number of subjects: 16
Study 17299516 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 16
Study 17299516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15598915 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin
Number of subjects: 412
Study 15598915 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alfa-2b plus ribavirin
Number of subjects: 412
Study 15598915 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin (HCV genotype 1 or 4)
Number of subjects: 412
Study 15598915 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alfa-2b plus ribavirin (HCV genotype 1 or 4)
Number of subjects: 412
Study 15598915 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin (HCV genotype 2, 3, or 5)
Number of subjects: 412
Study 15598915 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alfa-2b plus ribavirin (HCV genotype 2, 3, or 5)
Number of subjects: 412
Study 11758296 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment options for functional dyspepsia
Number of subjects: 18
Study 11758296 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific checklists with clinical and economical items
Number of subjects: 18
Study 11758296 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodologic rigor in economic analysis techniques
Number of subjects: 18
Study 9532994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole treatment during pregnancy
Number of subjects: 30363
Study 8080065 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days
Number of subjects: 135
Study 8080065 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 135
Study 8080065 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 135
Study 2642546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with CCNU and radiation therapy
Number of subjects: 198
Study 2642546 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 198
Study 998858 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings with gradually decreasing compression from ankle to groin
Number of subjects: 0
Study 998858 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31880284 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PRF
Number of subjects: 45
Study 31880284 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 45